Vandana Chaturvedi

Highly accomplished Scientist with extensive experience in in vitro and in vivo biology, immunology, and molecular biology. Demonstrated expertise in leading and executing preclinical studies to support IND filings for CAR-T therapy programs. Proven track record of developing and managing animal models, designing innovative strategies to enhance therapeutic efficacy, and contributing to scientific advancements in autoimmune diseases, infectious diseases, and pregnancy complications. Recognized for exceptional leadership, analytical skills, and contributions to team success.

Molecular Biology:

• Site-directed and random mutagenesis.
• PCR, DNA cloning, DNA isolation, primer design,
• Yeast transformation.
• RNA isolation
• cDNA synthesis
• rtPCR, qPCR and low-density arrays.
• Western blotting and immunoprecipitation

Cell Culture and Immunological Skills

• Intracellular staining and extensive flow cytometry expertise with BD FACS Calibur, FACS Canto, and LSR.
• Protein expression and purification.
• Transfection and LentiViral Transduction
• Production of monoclonal antibodies.
• ELISA and ELISPOTS
• Lentiviral RNA knockdown
• Extensive work with Primary human and mouse T cells
• T cell proliferation and suppression assays
• Co culture assays and MLR.
• Magnetic cell separation and purification (MACS)
• Flow cytometry cell separation and purification (FACS)
• Antibody labeling and antibody testing, LPS testing,
• Validation of antibody targets in human and mouse T cells
• Luminex assays
• Biosafety level 2 experience

Invivo Models

• Xenograft tumor models
• Testing small molecules as therapeutics in PID
• Humanized mouse models
• Homeostasis assay
• Inflammatory bowel disease
• Metastatic tumor model
• Acute graft versus host disease
• Mouse models of Infection and non infection mediated Pregnancy complications
• Mouse models of CIA

• Chaturvedi V, Lakes N, Tran M, Castillo N and Jordan MB. JAK inhibition for murine HLH requires complete blockade of IFN signaling and is limited by toxicity of JAK2 inhibition. Blood 138 (12):1034-1039, 2021
• Chaturvedi V, Marsh RA, Lorenz, AZ, Owsley E, Chaturvedi V, Nguyen CT, Goldman JR, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Jeng M, Naqvi A, Allen CE, Wong HR and Jordan MB."T cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis" Blood 137(17):2337-2346, 2021.
• McNally, Millen SH, Chaturvedi V, Lakes N, Terrell CE, Elfers EE, Carroll KR, Hogan SP, Andreassen PR, Kanter J, Allen CE, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Joyce M, Hildeman DA, Katz JD, Jordan MB. "Manipulating DNA Damage-Response Signaling for the Treatment of Immune-Mediated Diseases." PNAS 114(4): 4782-4791. 2017
• Cappelletti M, Presicce P, Lawson M.J, Chaturvedi V, Stankiewicz TE, Vanoni S, Harley ITW, McALees JW, Giles DA, Fernanadez, MME, Rueda CR, Senthamaraikannan P,Sun X, Karns R, Hoebe K, Jannsen EM, Karp CL, Hildeman DA, Hogan SP, Kallapur SG, Chougnet CA, Way SS, Divanovic S. Journal of Clinical Investigation. 125(4):1713-25. 2017
• Redecke V, Chaturvedi V, Kuriakose J, Häcker H. SHARPIN controls the development of regulatory T cells. Immunology 148(2): 216-26. 2016
• Chaturvedi V, Ertelt JM, Jiang TT, Kinder JM, Xin L, and Way,SS. CXCR3 blockade protects against Listeria monocytogenes infection-induced fetal wastage. Journal of Clinical Investigation. 125(4):1713-25. 2015
• Jiang TT, Chaturvedi V, Ertelt JM, Xin L, Clark DR, Kinder JM and Way,SS. Commensal enteric bacteria lipopolysaccharide impairs host defense against disseminated Candida albicans fungal infection. Mucosal Immunology 8(4):886-95 2014.
• Clark DR, Chaturvedi V, Kinder JM, Jiang TT, Xin L, Ertelt JM, and Way,SS. Perinatal Listeria monocytogenes susceptibility despite preconception priming and maintenance of pathogen-specific CD8+ T cells during pregnancy. Cellular and Molecular Immunology: 11(6):595-605. 2014.
• Xin L, Jiang TT, Chaturvedi V, Kinder JM, Ertelt JM, Rowe JH, Steinbrecher KA and Way SS. Commensal microbes drive intestinal inflammation by IL-17-producing CD4+ T cells through ICOSL and OX40L costimulation in the absence of B7-1 and B7-2. PNAS: 111(29): 10672-10677. 2014.
• Xin L, Rowe JH, Ertelt JM, Jiang TT, Kinder JM, Chaturvedi V, Elahi S and Way SS. Committed Th1 CD4+ T cell differentiation blocks pregnancy induced Foxp3 expression with antigen specific fetal loss. Cutting Edge: J Immunol. 192(7): 2970-4. 2014.
• Kinder JM, Jiang TT, Clark DR, Chaturvedi V, Xin L, Ertelt JM, Way SS. Pregnancy-induced maternal regulatory T cells, bona fide memory or maintenance by antigenic reminder from fetal cell microchimerism? Chimerism 19: 5(1): 1-4. 2014.
• Elahi S, Ertelt JM, Kinder JM, Jiang TT, Zhang X, Xin L, Chaturvedi V, Strong BS, Qualls JE, Steinbrecher KA, Kalfa TA, Shaaban AF, Way SS. Immunosuppressive CD71 erythroid cells compromise neonatal host defense against infection. Nature 504 (7478): 158-162. 2013.
• Redecke V, Wu R, Zhou J, Finkelstein David, Chaturvedi V, High AA, Häcker H Hematopoietic progenitor cell lines with myeloid and lymphoid potential. Nature Methods, 10: 795-803, 2013.
• Jones LL, Chaturvedi V, Uyttenhove C, Van Snick J, Vignali DAA. Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family. Molecular Immunology, 51 (2): 234-244, 2012.
• Collison LW, Delgoffe GW, Guy C, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ, Vignali DAA Unconventional IL-35 receptor composition and signaling. Nature Immunology, 13: 290-299, 2012.
• Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Finkelstein D, Forbes K, Workman CJ, BrownSA, JonesML,Rehg JE, ArtisD, Turk, M.J Vignali DAA Interleukin-35-mediated induction of a novel regulatory T cell population Nature Immunology, 11: 1093-1101, 2010.
• Collison LW, Pillai RM, Chaturvedi V, Vignali DAA. Regulatory T cell suppression is potentiated by target T cells in a cell contact IL-35 and IL-10 dependent manner. J Immunol 182: 6121-6128, 2009